Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Starboard gauges Bristol-Myers shareholder support for Celgene deal

Stock MarketsFeb 15, 2019 09:15PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: Jeff Smith, CEO of Starboard Value, L.P., speaks at a panel discussion at the SALT conference in Las Vegas

By Svea Herbst-Bayliss and Greg Roumeliotis

(Reuters) - Activist hedge fund Starboard Value LP has asked a proxy solicitor to probe the level of support among Bristol-Myers Squibb (NYSE:BMY) Co shareholders for the U.S. drug maker's $74 billion deal to buy Celgene Corp (NASDAQ:CELG), people familiar with the matter said on Friday.

The acquisition would be the biggest pharmaceuticals deal ever and would unite two major sellers of cancer drugs.

Starboard has not decided whether it would oppose the Celgene deal, the sources said. The fund, run by Jeff Smith, may take no action, the sources added.

Bristol-Myers shareholders will vote on the Celgene deal in April. While Celgene shares are pricing in some uncertainty over whether it will be completed, no major Bristol-Myers shareholder has voiced opposition publicly to the deal so far.

As of the end of trading on Friday, Bristol-Myers' cash-and-stock offer valued Celgene at $101.67 per share. Celgene shares ended trading at $90.69.

The sources asked not to be identified because the matter is confidential. Bristol-Myers and Starboard did not immediately respond to requests for comment.

Last week, Smith told CNBC in an interview that Starboard was "certainly interested in the story at Bristol-Myers." He declined to say whether the firm had a position it the stock.

"We evaluate those situations to determine whether we can have a positive impact. Bristol-Myers might fit that profile. It might not fit that profile. We haven't made that decision," Smith said.

Starboard has a track record of opposing deals. It tried to block Virginia-based meat giant Smithfield Foods' sale to Chinese company Shuanghui International in 2013, as well as aircraft component maker Rockwell Collins (NYSE:COL) Inc's acquisition of B/E Aerospace two years ago. Both deals were done.

The presence of an activist investor can encourage potential deal interlopers to step in. However, no rival suitor has so far emerged publicly, either for Bristol-Myers or for Celgene.

"Our impression from (Bristol-Myers) management's long-term focus and biopharma executive commentary is that the probability of a third party buyer for Bristol-Myers before the Celgene vote in April is very low," BMO analysts wrote in a research note on Thursday.

"We do not believe an activist can change that."

Starboard is known for being an influential investor that often pushes for operational improvements. It scored a boardroom coup at Darden Restaurants (NYSE:DRI) where it ousted all board members five years ago.

Starboard gauges Bristol-Myers shareholder support for Celgene deal
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email